Semaglutide improved maximum walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.

Cancer drugs conferring low or no therapeutic benefits accounted for $6.7 billion in post-rebate Medicare spending in 2022.

Older patients have divergent immune phenotypes at baseline that persist during immune checkpoint inhibitor therapy.

Fibrate therapy may lower the risks of mortality and progression to end-stage kidney disease (ESKD), despite raising the risk for new onset stage 3 or higher chronic kidney disease (CKD), a new study ...

Residual nodal disease following neoadjuvant chemotherapy for upper tract urothelial carcinoma (UTUC) indicates an especially high-risk population.

The HUGO robotic-assisted surgery system showed a high surgical success rate and favorable rates of grade 3 complications.

There have been no prospective studies comparing stent use vs nonuse after ureteroscopy for uncomplicated renal stones.

There are currently no proven therapies that reduce cisplatin-induced acute kidney injury (AKI) in patients with cancer.

Although recommended, many patients with metastatic clear cell RCC still don’t receive immune checkpoint inhibitor-based combinations as first-line treatment.

An investigator reported updated findings from the phase 2/3 study QUILT 3.032 using a July 15, 2024 data cutoff.

Recurrence in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer is common, and there have been a lack of alternative treatments to TURBT.

BOND-003 evaluated the efficacy and safety of cretostimogene grenadenorepvec, an oncolytic immunotherapy, in patients with carcinoma in situ BCG-unresponsive NMIBC.